• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铁氧体增强黑血心血管磁共振成像。

Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.

机构信息

Diagnostic Cardiovascular Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Division of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.

出版信息

J Cardiovasc Magn Reson. 2017 Dec 28;19(1):106. doi: 10.1186/s12968-017-0422-y.

DOI:10.1186/s12968-017-0422-y
PMID:29284494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5745904/
Abstract

BACKGROUND

Bright-blood and black-blood cardiovascular magnetic resonance (CMR) techniques are frequently employed together during a clinical exam because of their complementary features. While valuable, existing black-blood CMR approaches are flow dependent and prone to failure. We aim to assess the effectiveness and reliability of ferumoxytol enhanced (FE) Half-Fourier Single-shot Turbo Spin-echo (HASTE) imaging without magnetization preparation pulses to yield uniform intra-luminal blood signal suppression by comparing FE-HASTE with pre-ferumoxytol HASTE imaging.

METHODS

This study was IRB-approved and HIPAA compliant. Consecutive patients who were referred for FE-CMR between June 2013 and February 2017 were enrolled. Qualitative image scores reflecting the degree and reliability of blood signal suppression were based on a 3-point Likert scale, with 3 reflecting perfect suppression. For quantitative evaluation, homogeneity indices (defined as standard deviation of the left atrial signal intensity) and signal-to-noise ratios (SNR) for vascular lumens and cardiac chambers were measured.

RESULTS

Of the 340 unique patients who underwent FE-CMR, HASTE was performed in 257. Ninety-three patients had both pre-ferumoxytol HASTE and FE-HASTE, and were included in this analysis. Qualitative image scores reflecting the degree and reliability of blood signal suppression were significantly higher for FE-HASTE images (2.9 [IQR 2.8-3.0] vs 1.8 [IQR 1.6-2.1], p < 0.001). Inter-reader agreement was moderate (k = 0.50, 95% CI 0.45-0.55). Blood signal suppression was more complete on FE-HASTE images than on pre-ferumoxytol HASTE, as indicated by lower mean homogeneity indices (24.5 [IQR 18.0-32.8] vs 108.0 [IQR 65.0-170.4], p < 0.001) and lower blood pool SNR for all regions (5.6 [IQR 3.2-10.0] vs 21.5 [IQR 12.5-39.4], p < 0.001).

CONCLUSION

FE-HASTE black-blood imaging offers an effective, reliable, and simple approach for flow independent blood signal suppression. The technique holds promise as a fast and routine complement to bright-blood cardiovascular imaging with ferumoxytol.

摘要

背景

在临床检查中,由于其互补特性,经常同时使用亮血和黑血心血管磁共振(CMR)技术。虽然这些方法很有价值,但现有的黑血 CMR 方法依赖于血流,并且容易出现故障。我们旨在评估无磁化准备脉冲的铁氧体增强(FE)半傅立叶单 shot 涡轮自旋回波(HASTE)成像的有效性和可靠性,通过比较 FE-HASTE 与预铁氧体 HASTE 成像,以产生均匀的管腔内血液信号抑制。

方法

本研究获得了机构审查委员会的批准和符合 HIPAA 标准。连续入组 2013 年 6 月至 2017 年 2 月期间因 FE-CMR 而转介的患者。基于 3 分李克特量表评估反映血液信号抑制程度和可靠性的定性图像评分,3 分表示完全抑制。进行定量评估时,测量左心房信号强度的标准差(定义为均匀性指数)和血管腔和心腔的信噪比(SNR)。

结果

在 340 例接受 FE-CMR 的患者中,257 例行 HASTE 检查。93 例患者均进行了预铁氧体 HASTE 和 FE-HASTE 检查,并纳入本分析。FE-HASTE 图像的血液信号抑制程度和可靠性的定性图像评分明显更高(2.9[IQR 2.8-3.0] 比 1.8[IQR 1.6-2.1],p<0.001)。两位读者之间的一致性为中度(k=0.50,95%CI 0.45-0.55)。FE-HASTE 图像上的血液信号抑制更完全,表明平均均匀性指数较低(24.5[IQR 18.0-32.8] 比 108.0[IQR 65.0-170.4],p<0.001),所有区域的血池 SNR 均较低(5.6[IQR 3.2-10.0] 比 21.5[IQR 12.5-39.4],p<0.001)。

结论

FE-HASTE 黑血成像提供了一种有效、可靠且简单的血流独立血液信号抑制方法。该技术有望成为铁氧体增强后的快速常规亮血心血管成像的补充方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/e5d86bcd25d2/12968_2017_422_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/4478c2a8c187/12968_2017_422_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/25f31e30b129/12968_2017_422_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/daa37a2fadca/12968_2017_422_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/b3b59da4e76f/12968_2017_422_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/cc3eba1928df/12968_2017_422_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/155cd943ff77/12968_2017_422_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/6105754b9005/12968_2017_422_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/e5d86bcd25d2/12968_2017_422_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/4478c2a8c187/12968_2017_422_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/25f31e30b129/12968_2017_422_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/daa37a2fadca/12968_2017_422_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/b3b59da4e76f/12968_2017_422_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/cc3eba1928df/12968_2017_422_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/155cd943ff77/12968_2017_422_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/6105754b9005/12968_2017_422_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e11/5745904/e5d86bcd25d2/12968_2017_422_Fig8_HTML.jpg

相似文献

1
Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.铁氧体增强黑血心血管磁共振成像。
J Cardiovasc Magn Reson. 2017 Dec 28;19(1):106. doi: 10.1186/s12968-017-0422-y.
2
High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion.高分辨率、三维 Ferumoxytol 增强心血管磁共振静脉造影在中心静脉阻塞中的应用。
J Cardiovasc Magn Reson. 2019 Mar 11;21(1):17. doi: 10.1186/s12968-019-0528-5.
3
4D MUSIC CMR: value-based imaging of neonates and infants with congenital heart disease.4D 磁共振心肌灌注成像:先天性心脏病新生儿和婴儿的基于价值的成像
J Cardiovasc Magn Reson. 2017 Apr 3;19(1):40. doi: 10.1186/s12968-017-0352-8.
4
Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.非诺多泮作为3T磁共振血管造影术中的一种超说明书使用造影剂:一项儿童试点研究。
Pediatr Radiol. 2015 Jun;45(6):831-9. doi: 10.1007/s00247-014-3226-3. Epub 2014 Nov 27.
5
4D flow image quality with blood pool contrast: a comparison of gadofosveset trisodium and ferumoxytol.使用血池造影剂的4D血流图像质量:钆布醇三钠与铁羧麦芽糖的比较
Int J Cardiovasc Imaging. 2018 Feb;34(2):273-279. doi: 10.1007/s10554-017-1224-x. Epub 2017 Sep 8.
6
Macrophage Imaging of Cerebral Aneurysms with Ferumoxytol: an Exploratory Study in an Animal Model and in Patients.利用菲洛托醇对脑动脉瘤进行巨噬细胞成像:在动物模型和患者中的探索性研究
J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2055-2064. doi: 10.1016/j.jstrokecerebrovasdis.2016.10.026. Epub 2017 Jul 31.
7
The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence.快速及超快T2加权磁共振成像序列在肝脏钆铁葡胺增强中的价值:与传统自旋回波序列的比较
Radiat Med. 2000 Mar-Apr;18(2):97-105.
8
Improved high-resolution pediatric vascular cardiovascular magnetic resonance with gadofosveset-enhanced 3D respiratory navigated, inversion recovery prepared gradient echo readout imaging compared to 3D balanced steady-state free precession readout imaging.与三维平衡稳态自由进动读出成像相比,使用钆弗塞特增强的三维呼吸导航、反转恢复准备梯度回波读出成像改善了高分辨率儿科血管心血管磁共振成像。
J Cardiovasc Magn Reson. 2016 Nov 2;18(1):74. doi: 10.1186/s12968-016-0296-4.
9
Intermodality feature fusion combining unenhanced computed tomography and ferumoxytol-enhanced magnetic resonance angiography for patient-specific vascular mapping in renal impairment.联合平扫 CT 和 Ferumoxytol 增强磁共振血管成像的多模态特征融合在肾功能损害患者的个体化血管成像中的应用。
J Vasc Surg. 2020 May;71(5):1674-1684. doi: 10.1016/j.jvs.2019.08.240. Epub 2019 Nov 14.
10
Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study.品牌 ferumoxytol 与两种给药方案的通用 ferumoxytol 比较:一项心脏 MRI 图像质量研究。
Pediatr Radiol. 2023 Dec;53(13):2622-2632. doi: 10.1007/s00247-023-05778-4. Epub 2023 Oct 14.

引用本文的文献

1
A comprehensive evaluation of the left atrium using cardiovascular magnetic resonance.使用心血管磁共振对左心房进行全面评估。
J Cardiovasc Magn Reson. 2025 Feb 5;27(1):101852. doi: 10.1016/j.jocmr.2025.101852.
2
Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.揭开下一代MRI造影剂的面纱:关于铁羧麦芽糖增强MRI的当前见解与展望
Natl Sci Rev. 2024 Feb 7;11(5):nwae057. doi: 10.1093/nsr/nwae057. eCollection 2024 May.
3
Novel Gadolinium-Free Ultrasmall Nanostructured Positive Contrast for Magnetic Resonance Angiography and Imaging.

本文引用的文献

1
What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.黑框警告告诉了我们什么?使用铁羧麦芽糖作为磁共振成像造影剂的安全操作。
AJNR Am J Neuroradiol. 2017 Jul;38(7):1297-1302. doi: 10.3174/ajnr.A5188. Epub 2017 May 11.
2
Ferumoxytol vs. Gadolinium agents for contrast-enhanced MRI: Thoughts on evolving indications, risks, and benefits.对比增强磁共振成像中,铁羧麦芽糖与钆类造影剂的比较:关于不断变化的适应证、风险和益处的思考
J Magn Reson Imaging. 2017 Sep;46(3):919-923. doi: 10.1002/jmri.25580. Epub 2017 Feb 3.
3
Improved dark blood imaging of the heart using radial balanced steady-state free precession.
新型无钆超小纳米结构正对比剂用于磁共振血管造影和成像。
Nano Lett. 2023 Jun 28;23(12):5497-5505. doi: 10.1021/acs.nanolett.3c00665. Epub 2023 Jun 10.
4
Fractional myocardial blood volume by ferumoxytol-enhanced MRI: Estimation of ischemic burden.铁磁共振增强 MRI 检测心肌血容量分数:评估缺血负担。
Magn Reson Med. 2023 Apr;89(4):1557-1566. doi: 10.1002/mrm.29530. Epub 2022 Nov 16.
5
Ferumoxytol-enhanced magnetic resonance T1 reactivity for depiction of myocardial hypoperfusion.铁氧体增强磁共振 T1 反应性用于显示心肌低灌注。
NMR Biomed. 2021 Jul;34(7):e4518. doi: 10.1002/nbm.4518. Epub 2021 Apr 8.
6
Estimation of fractional myocardial blood volume and water exchange using ferumoxytol-enhanced magnetic resonance imaging.使用 Ferumoxytol 增强磁共振成像估计心肌血容量分数和水交换。
J Magn Reson Imaging. 2021 Jun;53(6):1699-1709. doi: 10.1002/jmri.27494. Epub 2020 Dec 31.
7
Black-Blood Contrast in Cardiovascular MRI.心血管磁共振中的黑血对比。
J Magn Reson Imaging. 2022 Jan;55(1):61-80. doi: 10.1002/jmri.27399. Epub 2020 Oct 19.
8
Journal of Cardiovascular Magnetic Resonance: 2017/2018 in review.心血管磁共振杂志:2017/2018 年度回顾。
J Cardiovasc Magn Reson. 2019 Dec 30;21(1):79. doi: 10.1186/s12968-019-0594-8.
9
Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.多中心安全性和铁氧体用于 MRI 诊断的标签外使用的实践
Radiology. 2019 Dec;293(3):554-564. doi: 10.1148/radiol.2019190477. Epub 2019 Oct 22.
10
Journal of Cardiovascular Magnetic Resonance 2017.《心血管磁共振杂志》 2017 年刊
J Cardiovasc Magn Reson. 2018 Dec 28;20(1):89. doi: 10.1186/s12968-018-0518-z.
使用径向平衡稳态自由进动改善心脏的黑血成像。
J Cardiovasc Magn Reson. 2016 Oct 19;18(1):69. doi: 10.1186/s12968-016-0293-7.
4
MRI with ferumoxytol: A single center experience of safety across the age spectrum.使用铁羧麦芽糖的磁共振成像:一个涵盖各年龄段安全性的单中心经验。
J Magn Reson Imaging. 2017 Mar;45(3):804-812. doi: 10.1002/jmri.25412. Epub 2016 Aug 2.
5
Cardiovascular MRI with ferumoxytol.使用铁羧麦芽糖的心血管磁共振成像。
Clin Radiol. 2016 Aug;71(8):796-806. doi: 10.1016/j.crad.2016.03.020. Epub 2016 May 21.
6
Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.用于儿童和青年成人磁共振成像的菲立磁安全性报告。
Invest Radiol. 2016 Apr;51(4):221-227. doi: 10.1097/RLI.0000000000000230.
7
Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.非那米星作为静脉造影剂在儿科患者和年轻成人中的血流动力学安全性和有效性。
Magn Reson Imaging. 2016 Feb;34(2):152-8. doi: 10.1016/j.mri.2015.10.019. Epub 2015 Oct 28.
8
Iron deficiency anaemia.缺铁性贫血。
Lancet. 2016 Feb 27;387(10021):907-16. doi: 10.1016/S0140-6736(15)60865-0. Epub 2015 Aug 24.
9
Emerging applications for ferumoxytol as a contrast agent in MRI.ferumoxytol作为磁共振成像造影剂的新兴应用。
J Magn Reson Imaging. 2015 Apr;41(4):884-98. doi: 10.1002/jmri.24691. Epub 2014 Jun 30.
10
A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.一项铁氧体对比蔗糖铁治疗口服铁剂治疗史不佳的缺铁性贫血患者的 III 期、随机、开放性试验。
Am J Hematol. 2014 Jun;89(6):646-50. doi: 10.1002/ajh.23712.